Insider Buying: Bausch Health Companies Inc (BHC) CFO Acquires 10,000 Shares of Stock
Bausch Health Companies Inc (NYSE:BHC) CFO Paul Herendeen acquired 10,000 shares of the firm’s stock in a transaction dated Friday, September 14th. The stock was bought at an average cost of $22.61 per share, for a total transaction of $226,100.00. The purchase was disclosed in a document filed with the SEC, which is available through this link.
Shares of NYSE:BHC traded up $0.20 during trading on Monday, hitting $22.55. 290,163 shares of the company’s stock were exchanged, compared to its average volume of 4,156,250. The company has a current ratio of 1.14, a quick ratio of 0.89 and a debt-to-equity ratio of 6.99. Bausch Health Companies Inc has a 52-week low of $10.94 and a 52-week high of $27.79. The stock has a market capitalization of $8.21 billion, a P/E ratio of 5.81, a P/E/G ratio of 0.34 and a beta of -0.43.
Bausch Health Companies (NYSE:BHC) last released its earnings results on Tuesday, August 7th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.12. Bausch Health Companies had a positive return on equity of 27.83% and a negative net margin of 20.60%. The firm had revenue of $2.13 billion during the quarter, compared to analysts’ expectations of $2.05 billion. research analysts predict that Bausch Health Companies Inc will post 3.47 earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in BHC. Private Management Group Inc. purchased a new position in Bausch Health Companies during the 2nd quarter valued at approximately $28,474,000. Tobam purchased a new position in Bausch Health Companies during the 2nd quarter valued at approximately $13,886,000. Van ECK Associates Corp purchased a new position in Bausch Health Companies during the 2nd quarter valued at approximately $11,494,000. Marshall Wace LLP purchased a new position in Bausch Health Companies during the 2nd quarter valued at approximately $2,974,000. Finally, Point View Wealth Management Inc. purchased a new position in Bausch Health Companies during the 2nd quarter valued at approximately $1,132,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Recommended Story: Average Daily Trade Volume – ADTV
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.